on 30 Apr 2024
Last Applicant/ Owned by
266 Northview Terrace
Springfield
US
07081
Serial Number
98088355 filed on 17th Jul 2023
Registration Number
N/A
Correspondent Address
BRET E. IELBOZICEVIC, IEL & RANCIS LLP
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Scientific and technological services, namely, scientific research, analysis and testing in the field of biology, pharmaceuticals and cell therapy; biological research and development; medical, pharmaceutical and biotechnological research Medical services, in particular in the field of immunotherapy, in particular in the field of immuno-oncology; medical services in the field of hyperproliferativRead More
Medical services, in particular in the field of immunotherapy, in particular in the field of immuno-oncology; medical services in the field of hyperproliferative diseases; medical services in the field of cancer; medical services in the field of anti-infectives; in particular all of the aforesaid services related to the use of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages
Scientific and technological services, namely, scientific research, analysis and testing in the field of biology, pharmaceuticals and cell therapy; biological research and development; medical, pharmaceutical and biotechnological research
Pharmaceutical preparations, in particular in the form of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; living cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; biological preparations in the form of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; therapeutic pharmaceuticals utilizing cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages in the treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; cell preparations such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections
Chemical and biochemical preparations for scientific purposes, in particular in the form of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for laboratory and experimentation purposes, in particular for conducting experimental assays, other than for medical or veterinary purposes; reagents for scientific and research use, namely, reagents such as proteins and nucleic acids for modifying cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages
No 98088355
No Service Mark
No NKLT-T001
No
No
No
No
No
No
No
No
| Status Date | Action Taken |
|---|---|
| 30th Apr 2024 | OICIAL GAZETTE PUBLICATION CONIRMATION E-MAILE |
| 30th Apr 2024 | PUBLISHE OR OPPOSITION |
| 10th Apr 2024 | NOTIICATION O NOTICE O PUBLICATION E-MAILE |
| 25th Mar 2024 | APPROVE OR PUB - PRINCIPAL REGISTER |
| 22nd Mar 2024 | ASSIGNE TO EXAMINER |
| 15th Aug 2023 | NEW APPLICATION OICE SUPPLIE ATA ENTERE |
| 20th Jul 2023 | NEW APPLICATION ENTERE |
